(Q34662884)

3 August 2017

1 reference

title

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia (English)

1 reference

3 August 2017

0 references

1 reference

1

Robak T

1 reference

3 August 2017

Kasznicki M

2

1 reference

3 August 2017

1 June 2002

1 reference

3 August 2017

1 reference

3 August 2017

16

1 reference

3 August 2017

1015-1027

1 reference

3 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402531

3 August 2017

0 references

cites work

Chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Key issues in the treatment of chronic lymphocytic leukaemia (CLL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

When and how to treat chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Clinical evaluation of CB 1348 in malignant lymphoma and related diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Chlorambucil in chronic lymphocytic leukemia: mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Chronic lymphocytic leukaemia treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Chlorambucil/Prednisone versus CHOP in Symptomatic Chronic Lymphocytic Leukemias of B-Cell type. A Randomized Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

The bioavailability of oral fludarabine phosphate is unaffected by food

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Infections in patients with chronic lymphocytic leukemia treated with fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Association of myelodysplastic changes with purine analogues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Cytotoxicity of 2-chlorodeoxadenosine (cladribine, 2-cdA) in combination with other chemotherapy drugs against two lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

The COP regimen is not a feasible treatment for advanced, refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Allogeneic and autologous transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402531

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402531

1 reference

PubMed ID

12040433

Dimensions Publication ID

3 August 2017

1035174434

0 references

Fatcat ID

release_kr7c3eczo5h7niuhegr4sf2eay

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kr7c3eczo5h7niuhegr4sf2eay

24 November 2022

mapped directly with Wikidata item

PubMed ID

12040433

1 reference

PubMed ID

12040433